<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845533</url>
  </required_header>
  <id_info>
    <org_study_id>H40380-31179-01</org_study_id>
    <nct_id>NCT00845533</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holley-Cotec Pharmaceuticals Co., LTD.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      This will be an open-label trial in Burkina Faso assessing the pharmacokinetics of the
      antimalarial combination of dihydroartemisinin/piperaquine (DP, Duocotexcin) in children.
      Dihydroartemisinin-piperaquine is a promising candidate for first-line therapy of malaria. We
      hypothesize that the disposition and pharmacokinetics of DP will be altered in children, and
      this will alter the efficacy and/or toxicity of DP. We will test this hypothesis in this
      open-label trial in Burkina Faso. The target population includes residents, aged 6 months to
      10 years in Bobo-Dioulasso. Children who present to the study clinics with symptoms
      suggestive of malaria will be screened with a thick blood smear. Subjects who meet selection
      criteria of treatment efficacy will be treated and followed up for 42 days. Pharmacokinetic
      sampling for DP will occur on selected follow-up days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Uncomplicated Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive screening thick blood smear

          2. Fever (&gt; 37.5ºC axillary) or history of fever in the previous 24 hours

          3. Age ≥ 6 months to 10 years

          4. Weight &gt; 5 kg

          5. Absence of any history of serious side effects to study medications

          6. No evidence of a concomitant febrile illness in addition to malaria

          7. No history of antimalarial use in the previous two weeks

          8. P. falciparum mono-infection

          9. Parasite density 2000-200,000/ul

         10. Provision of informed consent and ability to participate in 42-day follow-up

        Exclusion Criteria:

          1. Danger signs or evidence of severe malaria

          2. Hemoglobin levels &lt; 5.0 gm/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sunil Parikh, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip J Rosenthal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francsico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Bosco Ouedraogo, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Receherche en Sciences de la Sante Bobo-Dioulasso</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sunil Parikh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

